/Abbott%20Laboratories%20vials%20and%20Logo-by%20Melniov%20Dmitriy%20via%20Shutterstock.jpg)
It’s hard to look at Abbott Laboratories (ABT) without a sense of utter dread. That’s largely the consequence of ABT stock suffering a nearly 30% drop in value since the start of the year. Not surprisingly, the medical equipment specialist has “earned” an 88% Strong Sell rating from the Barchart Technical Opinion indicator. On the surface, it’s reasonable guidance based on the falling knives theory.
Further, the financial bullet points that got ABT stock into this mess are framed as problematic for investors. Primarily, the main concern centers on Abbott’s $23 billion acquisition of Exact Sciences. While management argues that the deal strengthens its long-term cancer diagnostics franchise, it also had to lower 2026 guidance because the acquisition would dilute earnings.
